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Among the various somatic mutations in the epidermal growth factor receptor (EGFR) found in non–small-cell 
lung cancer (NSCLC), the most common include inframe 
deletions of exon 19 (~45%) and the exon 21 L858R (~40%). 
Clinical trials have ascertained that the oral EGFR tyro-
sine kinase inhibitors (TKIs), gefitinib and erlotinib, lead to 
superior response rates (RRs) and progression-free survival 
(PFS) than standard chemotherapies in these NSCLCs.1,2 The 
reported RRs to gefitinib/erlotinib exceed 70%, with median 
PFS of approximately 9 to 12 months and overall survival 
times beyond 20 to 24months.1 Other less-prevalent EGFR 
mutations, such as the exon 18 G719X (~3%) and the exon 
21 L861Q (~2%) display RRs that exceed 50% and prolonged 
PFS in gefitinib/erlotinib-treated patients.3 EGFR exon 20 
insertion mutations (~5%) are associated with preclinical and 
clinical resistance to gefitinib/erlotinib.4
Other less-common EGFR mutations have not been 
completely characterized. This is the case of the exon 18 dele-
tion/insertion mutation delE709_T710insD. Herein, we report 
the response to erlotinib of an EGFR delE709_T710insD 
mutated NSCLC, and provide a review of the literature on the 
pattern of response to EGFR TKIs of this mutation type.
CASE REPORT
An 88-year-old white woman with a never-smoking 
history presented with stage IV NSCLC (adenocarcinoma) 
with multiple pulmonary nodules, an osteolytic rib lesion, and 
metastatic lymph nodes. Her Eastern Cooperative Oncology 
Group performance status was 0. The tumor, obtained from a 
transbronchial left lower lobe biopsy, did not contain an ALK 
translocation by fluorescence in situ hybridization. Tumor-
derived DNA was genotyped (using dideoxynucleotide 
sequencing) and found to have wild-type KRAS and the EGFR 
delE709_T710insD exon 18 mutation.
The patient was started on erlotinib 150 mg/day but was 
only able to tolerate this dose for 3 weeks. Because of intolera-
ble rash, gastrointestinal symptoms, and anorexia, the dose was 
reduced to erlotinib 75 mg/day. At the latter dose, the patient 
continued to have a characteristic EGFR-TKI–induced rash 
that was tolerable. Imaging studies after initiation of erlotinib 
demonstrated significant improvement of the patient’s tumor 
lesions (Fig. 1). Measurement of target lesions indicated that 
the best response was a reduction of 47% in the sum of the 
largest diameter of the target tumors’ dimensions, which clas-
sifies as a partial response (PR) using Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria. The last imaging 
study was obtained at the 4-month mark of therapy, and the 
clinical response was maintained for the 6 months of follow-
up. However, the patient decided to discontinue erlotinib at 
the 6-month mark of therapy. Further follow-up for clinical 
and radiographic progression was censored at that time point.
Frequency of EGFR delE709_T710insX 
among EGFR Mutated NSCLCs
We next evaluated the frequency of EGFR delE709_
T710insX mutations in the Wellcome Trust Sanger Institute 
Catalogue Of Somatic Mutations In Cancer (COSMIC) online 
database (http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?
action=bycancer&coords=AA%3AAA&start=1&end=1211&
ln=EGFR&sn=lung&display=Apply) of EGFR mutations in 
lung cancer as of March 13, 2012. EGFR delE709_T710insD 
was only identified in five of 9539 (0.05%) EGFR mutated 
NSCLCs and delE709_T710insX (insA/insG/insD) in seven 
of 9539 (0.07%) EGFR mutated NSCLCs.
Response of EGFR delE709_T710insD  
to EGFR TKIs
Two additional cases of patients whose tumors harbored 
EGFR delE709_T710insD and who received gefitinib have 
been reported.3,5 The calculated disease-control rate to EGFR 
TKIs for the EGFR delE709_T710insD cohort was 66% (2 
of 3 cases), and in two patients (including the case reported 
here), the PFS exceed 4 months. One of the cases was reported 
twice with divergent responses; in one publication as a PR5 
and in another as stable disease to gefitinib 250 mg/day3; in 
both the PFS was reported as 5 months. We assume this case 
had significant tumor regression but only met criteria for an 
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unconfirmed PR by RECIST criteria. The other case had pro-
gressive disease as best response to gefitinib 250 mg/day with 
a PFS of 0.9 months.3 These data indicate that the majority 
of NSCLCs with EGFR E709_T710delETinsD had tumor 
regression upon exposure to EGFR TKIs.
DISCUSSION
EGFR delE709_T710insD exon 18 mutations account 
for less than 0.1% of previously reported EGFR mutations in 
NSCLC. Our case and the two additional cases reported in 
the literature provide evidence that EGFR delE709_T710insD 
may lead to enhanced sensitivity to reversible EGFR TKIs. In 
vitro studies will be needed to confirm this assertion. The clin-
ical observation that patients with tumors with this mutation 
achieved radiographic tumor regression may be indicative that 
other patients with EGFR delE709_T710insD bearing tumors 
can benefit from gefitinib and/or erlotinib at their usual clini-
cal doses. In summary, EGFR delE709_T710insD is a rare but 
potentially EGFR-TKI–responsive mutation in NSCLC. The 
case presented here will be added to the Vanderbilt’s DNA-
mutation inventory to refine and enhance cancer treatment 
database (http://www.mycancergenome.org/direct.php), with 
the goal of enhancing the ability of oncologists to select thera-
pies for patients with uncommon EGFR-mutated NSCLCs.6
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FIGURE 1. Computed tomography 
images of the thorax of an adeno-
carcinoma of the lung harboring the 
EGFR delE709_T710insD mutation (A) 
before and (B) after erlotinib. EGFR, 
epidermal growth factor receptor. 
